Clinical trials: Solid Tumours
- Condition Solid Tumours
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Advanced Malignant Solid Tumors
A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor
This study is an open-label, multicenter, dose-escalation and dose-expansion Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of AK150…
- Trial name
- NCT07566247
- Testing
- AK150
- Where
- 3 sites in China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Akeso
Solid Tumour
A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole
This study will be conducted to quantify the magnitude of the effect of itraconazole co-administration on the PK of savolitinib.
- Trial name
- NCT04121910
- Testing
- Savolitinib, Itraconazole
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Metastatic Breast Cancer, Benign Breast Disease
China CellSearch Study
The study is designed to confirm the current indication (below) of the CellSearch® Circulating Tumor Cell Kit in metastatic breast cancer (MBC) patients for use of the kit in China.
- Trial name
- NCT01116869
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Medical, China
Neoplasms, Non-hematologic - Stage I-III
Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and "Healthy Controls"
The aim of this study is to employ genomic detection methodologies to measure the relative amount of tumor-derived nucleic acids in the blood of patients diagnosed with an early stage solid tumor who are either commencing…
- Trial name
- NCT03071809
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Lexent Bio, Inc.
Immune System
An Experimental Medicine Clinical Study to Compare Peripheral Immune System From Subjects Without Cancer Diagnosis and Patients With Solid Tumours.
The aim of the study is to gain knowledge concerning expression of immune markers on immune cell subpopulation of PBMCs from subjects without cancer diagnosis and cancer patients.
- Trial name
- IMMUNOPBMC (NCT05133128)
- Testing
- blood samples
- Where
- 2 sites in France
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Servier
Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as…
- Conditions
- Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06585488
- Testing
- BGB-53038, Tislelizumab, Cetuximab
- Where
- 17 sites in United States, Australia and 3 more
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Cancer, Neoplasm
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
The study enrolled advanced cancer participants with unresectable or metastatic disease who were refractory to or were not candidates for standard approved therapy.
- Trial name
- NCT04717375
- Testing
- SAR444881, Pembrolizumab, Cetuximab
- Where
- 18 sites in United States, Canada and 2 more
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy Volunteers, Pancreatic Ductal Adenocarcinoma
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC or Other Solid Tumors
- Conditions
- Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma
- Trial name
- RAD301 (NCT05799274)
- Testing
- RAD301 ([68Ga]-RAD301)
- Where
- 2 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Radiopharm Theranostics, Ltd
Solid Tumor
To Evaluate the Safety, Pharmacokinetic and the Effect of Food After Administration of ABN401 in Healthy Adult Volunteers
This randomized open-label, two-way crossover study is designed to evaluate the safety and pharmacokinetic characteristics of ABN401, and the effect of high-fat meal on the pharmacokinetic profiles of ABN401 and its metabolites…
- Trial name
- NCT05248074
- Testing
- High-fat meal (over 900 kcal), ABN401 (investigational product)
- Where
- South Korea
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Abion Inc
Solid Tumors Harboring NTRK Fusion
Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants
In this study, the researchers will compare 2 new tablet forms of BAY2731954 with liquid oral forms of BAY2731954. A maximum of 61 healthy volunteers aged 18 to 55 will be asked to participate. The study will have 2 parts.
- Trial name
- NCT04771390
- Testing
- Selitrectinib (BAY2731954) Adult tablet, Selitrectinib (BAY2731954) Pediatric tablet, Selitrectinib (BAY2731954) Oral solution
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Bayer
Non Small Cell Lung Cancer
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
- Trial name
- TRUST-II (NCT04919811)
- Testing
- Taletrectinib
- Where
- 77 sites in United States, Canada and 7 more
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Nuvation Bio Inc.
Solid Tumor
An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition
An open-label, randomized, single-dose, two-way crossover bioequivalence study to compare two strengths (10 mg and 20 mg) of IMP4297 capsules in healthy Chinese subjects under fed condition
- Trial name
- NCT05391048
- Testing
- IMP4297(20mg), IMP4297(10mg)
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Impact Therapeutics, Inc.
Solid Tumor, Adult
Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects
This is an open-label, non-randomized, clinical study to evaluate the drug interaction between itraconazole, rifampin or Cocktail and JMKX001899 in healthy subjects.
- Trial name
- NCT06348290
- Testing
- JMKX001899, Itraconazole, Midazolam
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Jemincare
Advanced Solid Tumor
Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Subjects
This is a one-arm, fixed-sequence study to compare the pharmacokinetic profiles of SHR6390 in absence and presence of prior administration of proton pump inhibitor Omeprazole.
- Trial name
- NCT04989829
- Testing
- SHR6390、Omeprazole
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Food Effect Study on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects
This study will adopt a randomized, open-label, two-period, 2-way crossover design to evaluate pharmacokinetics of a single oral dose of VC004 capsules under fasting and fed conditions in healthy subjects.
- Trial name
- NCT05528120
- Testing
- VC004 Capsules
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Bone Metastasis From Solid Tumors
Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults
A randomized, double-blind and parallel group study to compare the pharmacokinetic, pharmacodynamic, safety and immunogenicity of HS-20090 120mg（1.7ml）and Xgeva® in healthy adults.
- Trial name
- NCT04494373
- Testing
- HS-20090, Xgeva®
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Solid Tumours
To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
Study to assess the effect of Rifampicin on the pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
- Trial name
- NCT02046850
- Testing
- selumetinib, rifampicin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Advanced Solid Tumor
Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
The purpose of this study is to evaluate the Effect of Omeprazole on the Pharmacokinetics of Fluzoparib in Healthy male Adults.
- Trial name
- NCT04108676
- Testing
- Fluzoparib, Omeprazole
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Small Cell Lung Cancer, Solid Tumors
A Study of AL8326 in Healthy Subjects
This experiment plans to enroll 6-8 healthy male subjects in China, and ultimately collect complete test samples and data from at least 6 subjects as the standard.
- Trial name
- NCT07132957
- Testing
- 14C-labeled AL8326
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Advenchen Laboratories Nanjing Ltd.
Advanced Solid Tumors
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers
This is a double blind Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of DN1406131, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme…
- Trial name
- NCT03641794
- Testing
- DN1406131
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.